P/B
1,3
Moleculin Biotech
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
$15.1M
Market Cap • 9/18/2026
2015
(11 years)
Founded
2016
(10 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
0,1
BVPS
3,4
EPS
8,6
Market Cap
Market Cap
15,1M
EV
7,9M
EV/Revenue
0
EV/EBITDA
-0,3
EV/EBIT
-0,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-166,6%
Total Yield
-166,6%
Payout
0%
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,5%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
6,3%
CAGR Net Income 5Y
15,5%
CAGR OCF 5Y
6,1%
Leverage
N.D./EBITDA
0,2
Debt/Equity
0%
Current Ratio
0,9
Quick Ratio
0,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!